Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.5%. By the end of trading, Santarus fell $0.94 (-3.9%) to $23.20 on average volume. Throughout the day, 1,606,607 shares of Santarus exchanged hands as compared to its average daily volume of 1,416,300 shares. The stock ranged in price between $23.02-$24.30 after having opened the day at $24.23 as compared to the previous trading day's close of $24.14. Other companies within the Drugs industry that declined today were:

Mast Therapeutics



), down 37.8%,

Biocryst Pharmaceuticals



), down 9.1%,

Prana Biotechnology



), down 8.1% and

BioDelivery Sciences International



), down 7.8%.

Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. Santarus has a market cap of $1.6 billion and is part of the health care sector. Shares are up 122.3% year to date as of the close of trading on Monday. Currently there are 4 analysts that rate Santarus a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.

On the positive front,

Vanda Pharmaceuticals



), up 44.2%,

Reliv' International



), up 32.7%,

Inovio Pharmaceuticals



), up 29.0% and

GW Pharmaceuticals PLC ADR



), up 16.5% , were all gainers within the drugs industry with




) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.